Altered microRNA Expression Profile in Synovial Fluid from Patients with Knee Osteoarthritis with Treatment of Hyaluronic Acid
The aim of this study was to investigate the microRNA (miRNA) expression pattern in synovial fluid from patients with knee osteoarthritis (OA) after treatment with intra-articular injection of hyaluronan (HA).
Twelve OA patients were enrolled in accordance with the Kellgren–Lawrence classification of knee OA. All patients received intra-articular injection of HA once a week for 5 weeks and were evaluated with the Western Ontario and McMaster Universities (WOMAC) index at baseline. TaqMan miRNA assay profiling was performed on synovial fluid RNAs extracted from OA patients pre-injection and after 5 weeks of treatment with HA. Validation was performed using independent samples, including ten healthy controls and ten matched OA patients.
Forty-three miRNAs (21 overexpressed miRNAs and 22 underexpressed miRNAs) were differentially expressed in OA patients before and after treatment with HA (P < 0.05, false discovery rate corrected). Further bioinformatics prediction by mirPath indicated that the differential miRNA signatures in synovial fluid extracted from the OA patients demonstrated primarily upregulation of the PI3K-Akt signaling pathway, mitogen-activated protein kinase signaling pathway, regulation of autophagy, mRNA surveillance pathway, and B cell receptor signaling pathway. In addition, TaqMan real-time reverse transcription polymerase chain reaction was performed for validation on miR-146a, miR-155, let-7a, miR-181a, miR-454, and let-7b, which were significantly changed in abundance, using an independent cohort of ten healthy controls and ten OA patients as compared with those with intra-articular injection of HA.
Our results demonstrated that dysregulation in miRNAs in synovial fluid from OA patients and their affected biologic cellular processes might play important role in OA pathogenesis and HA-mediated therapeutics.
KeywordsSynovial Fluid Nottingham Health Profile Synovial Fluid Sample Rheumatoid Arthritis Synovial Fibroblast Physical Function Subscale
The authors thank all of the patients who participated in this study and the staff from the Department of Orthopedics, Zhejiang Provincial People’s Hospital, Hangzhou, PR China.
Compliance with Ethical Standards
None of the authors have any financial relationships to report.
This study was supported by the Medical Scientific Research Foundation of Zhejiang Province, China (grant no. 2013KYB031) (Y. P. W, J. F. X), the National Natural Science Foundation of China (grant no. 81200113) (Y. P. W, J. F. X), the Fundamental Research Funds for the Central Universities (grant no. 2014FZA7014) (Y. P. W, J. F. X), the Natural Science Foundation of Zhejiang Province, China (grant no. LQ15H060003) (Y. P. W, J. F. X), and the Natural Science Foundation of Zhejiang Province, China (grant no. LY15H020005) (Y. P. W, J. F. X).
- 2.Lohmander LS, Dalen N, Englund G, Hamalainen M, Jensen EM, Karlsson K, et al. Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial. Hyaluronan Multicentre Trial Group. Ann Rheum Dis. 1996;55(7):424–31.PubMedCentralCrossRefPubMedGoogle Scholar
- 7.Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000;43(9):1905–1915Google Scholar
- 10.Ospelt C, Brentano F, Rengel Y, Stanczyk J, Kolling C, Tak PP, et al. Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum. 2008;58(12):3684–92.CrossRefPubMedGoogle Scholar
- 15.Raynauld JP, Torrance GW, Band PA, Goldsmith CH, Tugwell P, Walker V, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (part 1 of 2): clinical results. Osteoarthritis Cartilage. 2002;10(7):506–17.CrossRefPubMedGoogle Scholar
- 18.Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833–40.PubMedGoogle Scholar
- 24.Torrance GW, Raynauld JP, Walker V, Goldsmith CH, Bellamy N, Band PA, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (part 2 of 2): economic results. Osteoarthritis Cartilage. 2002;10(7):518–27.CrossRefPubMedGoogle Scholar